PITTSBURGH, May 22, 2012 /PRNewswire/ -- New recommendations from the American Society of Clinical Rheumatologists (ASCR), published in Postgraduate Medicine[1], highlight updated management

ISELIN, N.J., May 17, 2012 /PRNewswire/ -- Pharmos Corporation (OTC-PINK: PARS) today announced that it has successfully completed a proof-of-concept clinical trial using its compound levotofisopam

Teens with high levels of uric acid appear to be at increased risk for high blood pressure.

ISELIN, N.J., April 5, 2012 /PRNewswire/ -- Pharmos Corporation (OTC-PINK: PARS) today provided an update on the ongoing clinical trial using its compound levotofisopam (S-tofisopam) to treat

EAST BRUNSWICK, N.J., March 5, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc.